

OPEN ACCESS

APPROVED BY Liang Qiao, The University of Sydney, Australia

*CORRESPONDENCE
Frontiers Editorial Office
 research.integrity@frontiersin.org

RECEIVED 02 December 2024 ACCEPTED 02 December 2024 PUBLISHED 10 December 2024

CITATION

Frontiers Editorial Office (2024) Retraction: ACADL functions as a tumor suppressor in hepatocellular carcinoma metastasis by inhibiting matrix metalloproteinase 14. *Front. Oncol.* 14:1538134. doi: 10.3389/fonc.2024.1538134

COPYRIGHT

© 2024 Frontiers Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Retraction: ACADL functions as a tumor suppressor in hepatocellular carcinoma metastasis by inhibiting matrix metalloproteinase 14

Frontiers Editorial Office*

A Retraction of the Original Research Article

ACADL functions as a tumor suppressor in hepatocellular carcinoma metastasis

By Guo D, Zhang X, Cui H, Yu D, Zhang H, Shi X, Pang C, Li J, Guo W and Zhang S (2022) *Front. Oncol.* 12:821484. doi: 10.3389/fonc.2022.821484

The journal retracts the 2022 article cited above.

Following publication, concerns were raised regarding the integrity of the images in the published figures. The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers' policies.

This retraction was approved by the Chief Editors of Frontiers in Oncology and the Chief Executive Editor of Frontiers. The authors received a communication regarding the retraction and had a chance to respond. This communication has been recorded by the publisher.